Inhibition of Aeroallergen-lnduced Bronchial Eosinophilia by Azelastine in Guinea Pigs

Chand, N.; Nolan, K.; Diamantis, W.; Sofia, Duane

doi:10.1159/000236124

Cited by 12 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, histologie findings showed a lower number of inflammatory cells and mast cells in the mucosa at the pharyngeal orifice of the eustachian tube in animals without MEE than in those with MEE, in all groups except group D. Previous studies have demonstrated that AZ effectively inhibits allergic eosinophil infiltration and neutrophil infiltration in animals. 30 • 31 Therefore, the results of the present study support the theory that AZ suppresses the allergic reaction in the nasopharynx around the eustachian tube. Thus, AZ administration appeared to lead to improvement in eustachian tube function and result in clearance of MEE.…”

Section: Discussionsupporting

confidence: 87%

Efficacy of an Antiallergic Drug on Otitis Media with Effusion in Association with Allergic Rhinitis; An Experimental Study

Suzuki¹,

Kawauchi²,

Kerakawauchi³

et al. 1999

Ann Otol Rhinol Laryngol

View full text Add to dashboard Cite

The effect of an antiallergic drug on the evacuation of middle ear effusion (MEE) from the tubotympanum was investigated by means of an animal model with both otitis media with effusion (OME) and allergic rhinitis. Azelastine hydrochloride (AZ), an oral antiallergic drug, was administered and the presence of MEE was investigated. Serous MEE was seen in 12 of the 13 untreated control animals on the 11th day after the experimental OME was induced, whereas MEE was detected in 9 of the 13 animals administered 1 mg/kg of AZ, but only in 4 of the 13 animals administered 2 mg/kg of AZ. In addition, the effect of AZ on MEE production was also examined in an experimental OME animal model without allergic rhinitis. Middle ear effusion was observed in all OME animals that received 2 mg/kg AZ for 5 consecutive days, before and 3 days after the experimental OME was induced. Results of the present study indicate that AZ promotes the evacuation of MEE from the tubotympanum in the OME animal model associated with nasal allergy. These data suggest that an antiallergic drug may contribute to the therapy of OME patients in association with nasal allergy indirectly, by promoting evacuation of MEE due to inhibition of type I allergic reactions in the nasopharynx.

show abstract

Section: Discussionsupporting

confidence: 87%

Efficacy of an Antiallergic Drug on Otitis Media with Effusion in Association with Allergic Rhinitis; An Experimental Study

Suzuki¹,

Kawauchi²,

Kerakawauchi³

et al. 1999

Ann Otol Rhinol Laryngol

View full text Add to dashboard Cite

show abstract

“…Azelastine re duces BAL eosinophils in guinea pigs [12] and inhibits eosi nophil migration into the bronchi of dogs following antigen challenge [21], In addition, azelastine prevents eosinophil degranulation [22] and activation [23]. The release of gran ule proteins from eosinophils damages the airway epitheli um and augments airway hyperresponsiveness [24], The findings o f those EG2-positivc eosinophils decreased after azelastine treatment are supporting its anti-inflammatory action.…”

Section: Discussionmentioning

confidence: 98%

“…Azelastic is a novel compound with a broad spectrum of pharmac ological activity on airway inflammatory and smooth mus cle response [6], Azelastine acts as an inhibitor o f the syn thesis and release of bronchospastic mediators (e.g., histamine and serotonin) from mast cells, eosinophils, and other cells, following immunological ornonimmunological stimulation [7][8][9][10][11]. Azelastine inhibits allergic eosinophil infiltration in bronchoalveolar lavage (BAL) [12] and neu trophils in the lungs of guinea pigs [13]. Therapy with aze lastine has helped patients with asthma to reduce their use of concomitant antiasthma medications and has also decreased or stabilized asthma symptoms [14].…”

Section: Introductionmentioning

confidence: 99%

The Effect of Azelastine on the Infiltration of Inflammatory Cells into the Bronchial Mucosa and Clinical Changes in Patients with Bronchial Asthma

Hoshino¹,

Nakamura²

1997

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Azelastine is an oral antiallergic compound but there is no direct evidence of its anti-inflammatory actions in bronchial asthma. We examined the effect of azelastine on inflammatory cells infiltrating the bronchial mucosa and clinical symptoms in atopic asthma in a double-blind, parallel, randomized study. Methods: The study was completed by 13 subjects in the azelastine (4 mg/day) group and 11 subjects in the placebo group. Treatments were randomly administered for 3 months. Each subject recorded daily asthma symptoms and peak expiratory flow (PEF). Lung function and bronchial responsiveness to methacholine were measured before and after treatment. Fiberoptic bronchoscopy was performed and bronchial biopsies taken from segmental carinae before and after treatment with azelastine or placebo. Using each monoclonal antibody for eosinophils, mast cells, macrophages, and T lymphocytes we performed immunohistological staining on biopsy specimens. Results: Compared with the placebo-treated group, the azelastine-treated group exhibited significant improvement of asthma symptoms (p < 0.01), PEF (p < 0.01), PEF diurnal variation (p < 0.001), excluding forced expiratory volume in 1 s or airway responsiveness. This was accompanied by a reduction of EG2(+) eosinophils (p < 0.01), CD3(+) (p < 0.001), CD4(+) (p < 0.05), CD8(+) (p < 0.05) T lymphocytes, and CD25(+)-activated T lymphocytes (p < 0.001) in the bronchial mucosa. Significant correlations were found between clinical data and immunohistochemical parameters. Conclusion: These results demonstrated that the beneficial effects of azelastine in bronchial asthma may result from modulation of local bronchial inflammatory cell infiltration.

show abstract

Mucolytic activity of azelastine in mice and rats

et al. 1993

View full text Add to dashboard Cite

The mucolytic activity of azelastine, an antiallergic/antiasthmatic drug, in mice and rats was investigated. The oral administration of test compounds 30 min before phenol red i.p. injection stimulated dye secretion in the trachea of mice. The resulting oral ED50's (mg/kg) were: azelastine, 0.16; salbutamol, 2.5; N-acetylcysteine, 61.8; S-Carboxymethyl-l-cysteine, < 100; bromhexine, > 100; and potassium iodide, approximately 200. In rats, several drugs stimulated secretion of fluorescein sodium (FINa) in the tracheobronchial lumen. The resulting oral ED50's (mg/kg) were: azelastine, 0.33; terbutaline, 0.3; salbutamol, 0.89; and S-carboxymethyl-l-cysteine, 56.8. Terfenadine and diphenhydramine (1-10 mg/kg, p.o.) did not stimulate tracheal secretion in rats and mice. The mucolytic activity of azelastine may contribute to its overall effectiveness, including antitussive activity in asthmatics. Finally, this activity seems to be dissociated from its H1-histamine receptor blocking activity.

show abstract

Inhibition of Aeroallergen-lnduced Bronchial Eosinophilia by Azelastine in Guinea Pigs

Cited by 12 publications

References 11 publications

Efficacy of an Antiallergic Drug on Otitis Media with Effusion in Association with Allergic Rhinitis; An Experimental Study

Efficacy of an Antiallergic Drug on Otitis Media with Effusion in Association with Allergic Rhinitis; An Experimental Study

The Effect of Azelastine on the Infiltration of Inflammatory Cells into the Bronchial Mucosa and Clinical Changes in Patients with Bronchial Asthma

Mucolytic activity of azelastine in mice and rats

Contact Info

Product

Resources

About